121 related articles for article (PubMed ID: 8720577)
21. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine.
Löscher W; Hönack D
J Pharmacol Exp Ther; 1991 Feb; 256(2):432-40. PubMed ID: 1671593
[TBL] [Abstract][Full Text] [Related]
22. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats.
Schmidt WJ; Bubser M
Pharmacol Biochem Behav; 1989 Mar; 32(3):621-3. PubMed ID: 2544900
[TBL] [Abstract][Full Text] [Related]
23. Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551.
Mennini T; Miari A; Presti ML; Rizzi M; Samanin R; Vezzani A
Eur J Pharmacol; 1994 Dec; 271(1):93-101. PubMed ID: 7698217
[TBL] [Abstract][Full Text] [Related]
24. The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.
Hauber W; Münkle M
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jul; 354(2):179-86. PubMed ID: 8857595
[TBL] [Abstract][Full Text] [Related]
25. Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Kinoshita H; Hasegawa T; Kameyama T; Yamamoto I; Nabeshima T
Neurosci Lett; 1994 Jun; 174(1):101-4. PubMed ID: 7970141
[TBL] [Abstract][Full Text] [Related]
26. The effects of NMDA receptor antagonists at anticonvulsive doses on the performance of rats in the water maze task.
Ylinen A; Pitkänen M; Sirviö J; Hartikainen T; Sivenius J; Koivisto E; Riekkinen PJ
Eur J Pharmacol; 1995 Feb; 274(1-3):159-65. PubMed ID: 7768268
[TBL] [Abstract][Full Text] [Related]
27. Interactions between NMDA and AMPA/kainate receptors in the control of micturition in the rat.
Yoshiyama M; Roppolo JR; De Groat WC
Eur J Pharmacol; 1995 Dec; 287(1):73-8. PubMed ID: 8666029
[TBL] [Abstract][Full Text] [Related]
28. Protection by MK-801 against hypoxia-, excitotoxin-, and depolarization-induced neuronal damage in vitro.
Schurr A; Payne RS; Rigor BM
Neurochem Int; 1995 May; 26(5):519-25. PubMed ID: 7492949
[TBL] [Abstract][Full Text] [Related]
29. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.
Liljequist S; Cebers G; Kalda A
Biochem Pharmacol; 1995 Nov; 50(11):1761-74. PubMed ID: 8615854
[TBL] [Abstract][Full Text] [Related]
30. Effects of glutamate receptor antagonists on posthypoxic myoclonus in rats.
Jaw SP; Vuong QT; Nguyen M
Brain Res Bull; 1996; 40(3):163-6. PubMed ID: 8736576
[TBL] [Abstract][Full Text] [Related]
31. Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Maj J; Skuza G; Rogóz Z
J Neural Transm Park Dis Dement Sect; 1993; 6(1):53-62. PubMed ID: 8105798
[TBL] [Abstract][Full Text] [Related]
32. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
Moore NA; Blackman A; Awere S; Leander JD
Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
[TBL] [Abstract][Full Text] [Related]
33. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats.
Löscher W; Annies R; Hönack D
Eur J Pharmacol; 1993 Oct; 242(3):263-74. PubMed ID: 7904243
[TBL] [Abstract][Full Text] [Related]
34. Competitive NMDA receptor antagonists do not produce locomotor hyperactivity by a dopamine-dependent mechanism.
Ouagazzal A; Amalric M
Eur J Pharmacol; 1995 Dec; 294(1):137-46. PubMed ID: 8788425
[TBL] [Abstract][Full Text] [Related]
35. Effect of NMDA receptor antagonists on protein kinase activated by chronic morphine treatment.
Makimura M; Iwai M; Sugimoto H; Fukuda H
J Toxicol Sci; 1997 Feb; 22(1):57-64. PubMed ID: 9076657
[TBL] [Abstract][Full Text] [Related]
36. Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: involvement of supraspinal NMDA but not non-NMDA receptors.
Suh HW; Song DK; Choi YS; Kim YH
Life Sci; 1995; 56(8):PL181-5. PubMed ID: 7869834
[TBL] [Abstract][Full Text] [Related]
37. Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence.
Fundytus ME; Coderre TJ
Br J Pharmacol; 1994 Dec; 113(4):1215-20. PubMed ID: 7889275
[TBL] [Abstract][Full Text] [Related]
38. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice.
Czuczwar SJ; Borowicz KK; Kleinrok Z; Tutka P; Zarnowski T; Turski WA
Eur J Pharmacol; 1995 Aug; 281(3):327-33. PubMed ID: 8521917
[TBL] [Abstract][Full Text] [Related]
39. The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function.
Dall'Olio R; Rimondini R; Gandolfi O
Psychopharmacology (Berl); 1995 Apr; 118(3):310-5. PubMed ID: 7617824
[TBL] [Abstract][Full Text] [Related]
40. Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex.
Dereń-Wesołek A; Maj J
Pol J Pharmacol; 1993; 45(5-6):467-80. PubMed ID: 7912135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
